EP1863433A1 - Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition - Google Patents
Compositions and methods for increasing metabolism, thermogenesis and/or muscular definitionInfo
- Publication number
- EP1863433A1 EP1863433A1 EP06741359A EP06741359A EP1863433A1 EP 1863433 A1 EP1863433 A1 EP 1863433A1 EP 06741359 A EP06741359 A EP 06741359A EP 06741359 A EP06741359 A EP 06741359A EP 1863433 A1 EP1863433 A1 EP 1863433A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- increasing
- extract
- subject
- composition according
- thermogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Definitions
- the present invention relates to compositions and methods for increasing a person's natural metabolic rate, increasing thermogenesis or decreasing water retention.
- the present invention comprises a composition of a first combination that comprises green tea extract, anhydrous caffeine, and guarana powder; a second combination that comprises dandelion root extract, and juniper berry powder; and a third combination that comprises N-acetyl-L-tyrosine, and gynostemma pentaphyullum.
- the present invention may also comprise thiamin, pyridoxine, niacin, quercetin dehydrate, cayenne pepper powder, oolong tea extract, white tea extract, theobroma cocao extract, vinpocetine, yerba mate leaf powder, parsley powder extract, picamilone, and xanthinol nicotinate.
- the present invention provides methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject utilizing the invention.
- the present invention provides methods of reducing body fat mass leading to weight loss and improving muscular definition in subjects.
- the present invention provides a composition for increasing a subject's natural metabolic rate and/or decreasing water retention, thus reducing a subject's body fat mass leading to weight loss and improving visible muscular definition.
- Certain embodiments of the present invention include diet supplements.
- the present invention may allow a subject to burn more calories than the subject would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
- the present invention provides compositions and methods that decrease water retention in subjects.
- the composition and method may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
- a composition and related methods comprise: a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, anhydrous caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one or more of dandelion root extract, juniper berry powder, parsley powder (leaf) and cayenne pepper powder; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine.
- the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia, and/or xanthinol nicotinate.
- the present invention may further comprise ingredients such as, thiamin or any salts or esters thereof, niacin, xantinol nicotinate, picamilone, and pyridoxine or a salt thereof in any of its pharmaceutically acceptable forms.
- the diet supplement may be consumed in any form.
- the dosage form of the diet supplement may be as a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a caplet, or as a dietary gel.
- the dosage form of the diet supplement in accordance with these embodiments may be provided in accordance with customary processing techniques for herbal and/or diet supplements in any of the forms mentioned above.
- a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
- a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
- compositions according to the present invention may be employed in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in subjects.
- the compositions of the present invention are particularly advantageous for athletes and bodybuilders to improve muscular definition.
- the dosage amount of the compositions according to the present invention which is administered to a subject may vary depending on the desired effect, the body weight and other characteristics of the subject.
- the compositions according to the present invention are administered to the subject on a daily basis.
- the compositions according to the present invention are administered to the subject three times daily.
- the present invention also provides a method of increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject.
- the methods of the present invention include administering a composition to a subject.
- methods for reducing body fat mass leading to weight loss and thus improving visible muscular definition are provided.
- the administration of compositions according to the present invention allow a person's body to burn more calories than the person's body would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
- the methods of the present invention provide for the administration of compositions according to the present invention that decrease water retention.
- the administration of compositions according to the present invention may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
- compositions and related methods comprising a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one more of dandelion root extract, juniper berry powder, parsley powder (leaf), cayenne pepper powder, and xanthinol nicotinate; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine.
- the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia extract, and/or xanthinol nicotinate.
- compositions according to the present invention may be administered in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
- the methods of the present invention are particularly advantageous for athletes and bodybuilders to improve visible muscular definition.
- the methods of the present invention include a determination, and an administration, of an amount of a composition in accordance with factors such as the desired effect, the body weight and characteristics of the athlete.
- the present invention includes methods of administering compositions according to the invention to subjects on a daily basis or three times daily.
- the following composition is provided: green tea extract (0.4440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.2000 g), cayenne pepper powder (0.1000 g), n-acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), picamilone HCI (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010 g
- the example composition may be ingested 30 to 60 minutes prior to eating a meal.
- the example composition can also be consumed prior exercise to increase and athlete's training intensity.
- the example composition may be ingested 30 to 60 minutes prior to eating a meal.
- the example composition can also be consumed prior exercise to increase and athlete's training intensity.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66339605P | 2005-03-18 | 2005-03-18 | |
PCT/CA2006/000415 WO2006096996A1 (en) | 2005-03-18 | 2006-03-20 | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1863433A1 true EP1863433A1 (en) | 2007-12-12 |
EP1863433A4 EP1863433A4 (en) | 2009-09-09 |
Family
ID=36991257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06741359A Withdrawn EP1863433A4 (en) | 2005-03-18 | 2006-03-20 | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1863433A4 (en) |
AU (1) | AU2006225005A1 (en) |
CA (1) | CA2600301A1 (en) |
WO (1) | WO2006096996A1 (en) |
ZA (1) | ZA200708361B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2551622A1 (en) * | 2005-07-07 | 2007-01-07 | H3 Formulations Ltd. | Dietary supplement for enhancing skeletal muscle mass, decreasing muscleprotein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
US10881661B2 (en) * | 2008-06-13 | 2021-01-05 | International Ip Holdings Llc | Edible energy composition |
US20210077517A1 (en) * | 2008-06-13 | 2021-03-18 | International IP Holdings | Edible Energy Composition |
FR2938735B1 (en) * | 2008-11-21 | 2012-12-28 | Holymark | AMAIGRANT COMPOSITION, ESPECIALLY FOR SPORTS, ORAL ADMINISTRABLE AND FOOD SUPPLEMENT INTEGRATING SUCH A COMPOSITION. |
PL2440206T3 (en) | 2009-06-11 | 2018-12-31 | Dsm Ip Assets B.V. | Trigonellin as a muscle stimulant |
ES2386858B1 (en) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | NATURAL SLIMMING COMPOSITION. |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
WO2013168019A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neuropathic pain |
CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
JP2015519333A (en) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | Compositions and methods for the treatment of neurological disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
EP2892878A4 (en) | 2012-09-08 | 2016-02-24 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN107207403A (en) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | Composition and method for treating multiple sclerosis |
CN107108535B (en) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | Three-component salts of monomethyl fumarate with piperazine or ethylenediamine for the treatment of multiple sclerosis |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
JP6679616B2 (en) | 2015-01-06 | 2020-04-22 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
AU2019239797B2 (en) | 2018-03-20 | 2024-04-04 | Exerkine Corporation | Weight management composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277396B1 (en) * | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
US20040005368A1 (en) * | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
-
2006
- 2006-03-20 AU AU2006225005A patent/AU2006225005A1/en not_active Abandoned
- 2006-03-20 CA CA002600301A patent/CA2600301A1/en not_active Abandoned
- 2006-03-20 EP EP06741359A patent/EP1863433A4/en not_active Withdrawn
- 2006-03-20 WO PCT/CA2006/000415 patent/WO2006096996A1/en not_active Application Discontinuation
-
2007
- 2007-10-01 ZA ZA200708361A patent/ZA200708361B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277396B1 (en) * | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
US20040005368A1 (en) * | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "Pro-Cuts-Ephedra Free" SCIFITNESS, [Online] 19 November 2004 (2004-11-19), XP002535824 Retrieved from the Internet: URL:http://www.scifitauthentic.com/productdetail.asp?navid=2&pid=46> [retrieved on 2009-07-07] * |
KARAYEV ET AL: "Preclinical study of picamilon and benzaflavine" PHARMACOLOGICAL RESEARCH, vol. 31, 1 January 1995 (1995-01-01), page 262, XP022359432 ACADEMIC PRESS, LONDON, GB ISSN: 1043-6618 * |
See also references of WO2006096996A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006096996A1 (en) | 2006-09-21 |
ZA200708361B (en) | 2008-10-29 |
EP1863433A4 (en) | 2009-09-09 |
CA2600301A1 (en) | 2006-09-21 |
AU2006225005A1 (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1863433A1 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
US20060210653A1 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
US7989009B2 (en) | Composition and method for promoting weight loss | |
US20050249827A1 (en) | Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite | |
EP3590521B1 (en) | Synergistic dietary supplement compositions for enhancing physical performance and energy levels | |
US9220741B2 (en) | Weight loss formulation | |
US7943183B2 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
AU2007222860A1 (en) | Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis | |
Cherniack | Potential applications for alternative medicine to treat obesity in an aging population | |
WO2018112475A1 (en) | Energy compositions and methods | |
US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
US20080279967A1 (en) | Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid | |
US20130280367A1 (en) | Method and Composition for Increasing Energy and Focus | |
CA2751218C (en) | Weight loss formulation | |
CA2446254C (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
WO2011159850A2 (en) | Lip cosmetic formulations | |
PT103650B (en) | COMPOSITIONS OF VEGETABLE EXTRACTS | |
KR20050038766A (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
CA2588491A1 (en) | Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid profile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071017 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/522 20060101ALI20080213BHEP Ipc: A61K 36/82 20060101AFI20080213BHEP Ipc: A61K 36/38 20060101ALI20080213BHEP Ipc: A61K 31/4415 20060101ALI20080213BHEP Ipc: A61K 36/288 20060101ALI20080213BHEP Ipc: A61K 36/77 20060101ALI20080213BHEP Ipc: A61K 31/51 20060101ALI20080213BHEP Ipc: A61K 36/14 20060101ALI20080213BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RIPPED FORMULATIONS LTD. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HEUER, MARVIN, A. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090811 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20091001 |